Access to eculizumab
Article No. 375 6 September 2020 Earlier this year, aHUS alliance Global Action wrote to a number of contacts it has…
aHUS TRIALS WATCH 10
Article No. 331 8 March 2020 During his talk about potential complement inhibitors, Dr Richard Smith mentioned a ClinicalTrials.gov clinical trial…
Eculizumab- safe or not?
aHUS patients and carers raised the research topic : "Can the side effects of treatment using a complement inhibitor be distinguished…
Transplant research answers that matter to aHUS patients
These days a kidney transplant may not feature much in the thoughts of new onset aHUS patients, most of them can…
Atypical HUS in the Netherlands
Atypical HUS in the Netherlands - An aHUS Alliance interview with the Dutch research and clinical teams at Radboudumc, to include the broad importance of their CUREiHUS study and its potential impact for patients and physicians world wide.
NICE process begins it will soon be Christmas
In April 2013 we heard that NICE would not get to the evaluating and decision step until December 2013 , which…
South African Pediatric Nephrology: Global Panel Proposed for aHUS Drug Access
Dr Errol Gottlich and Professor Mignon McCulloch Resilience, fortitude and determination. These characteristics describe the South African doctor treating patients within a complex and changing…
Dr Ralf Reski on Moss-Made Biopharmaceuticals: aHUS Alliance Interview
The aHUS Alliance recently conducted an interview with Dr Ralf Reski, a professor and researcher in the field of…
aHUS Group Expectations for 2018 (continued)
Following aHUS India's response came two replies from The Netherlands and UK in Europe. Their expectations reflect a very different position…